Ra Medical Systems Announces the Presentation of Clinical Data at the European Heart Rhythm Association Congress

Ra Medical Systems, Inc. (NYSE American: RMED) (Ra Medical), a medical device and technology company focused on cardiac electrophysiology, announces that four abstracts with clinical data supporting its VIVO technology have been accepted for presentation at the European Heart Rhythm Association Congress (EHRA 2023) being held April 16-18, 2023 in Barcelona. VIVO, developed by Ra Medical’s wholly owned subsidiary Catheter Precision, is a proprietary AI system used to non-invasively identify the origin of ventricular arrhythmias prior to an ablation procedure.

“It is highly gratifying to present clinical data to the many electrophysiology thought leaders at the largest European meeting solely focused on arrhythmia management and treatment,” said David Jenkins, Ra Medical Systems Executive Chairman. “All four abstracts with VIVO clinical data submitted by leading physicians to the Congress were accepted for presentation following an extensive peer-review process. To have one-hundred percent acceptance of submitted abstracts is rare and I believe indicative of the positive impact VIVO is having on ventricular ablation procedures. We view this recognition as a major milestone in gaining clinical acceptance by both EP thought leaders and the larger medical community.”

About EHRA
EHRA is a branch of the European Society of Cardiology (ESC). The European Heart Rhythm Association (EHRA) is the leading network of European Cardiac Rhythm Management with more than 4,100 members around the globe, including physicians, arrhythmia experts, electrophysiologists, nurses and allied professionals. The EHRA Congress brings together industry professionals to learn, discover and educate them on new and innovative technologies that impact arrhythmia treatment.

About VIVO
Catheter Precision’s VIVO™ (View Into Ventricular Onset) is a non-invasive 3D imaging system that enables physicians to identify the origin of arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.